Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes
This analysis demonstrated that the health and economic burden of RSV would be substantially reduced in all infants experiencing their first RSV season in the UK (including term, preterm, and palivizumab-eligible infants) as a result of a universal immunization strategy with nirsevimab.
Authors
- Mersha Chetty
- Robert Musci (ORCID: https://orcid.org/0000-0002-6521-6967)
- Aditya Sardesai (ORCID: https://orcid.org/0000-0002-4250-4747)
- Alexia Kieffer (ORCID: https://orcid.org/0009-0004-5735-195X)
- Richard Hudson (ORCID: https://orcid.org/0000-0003-2661-5348)
- Gerald Moncayo (ORCID: https://orcid.org/0000-0002-5718-7772)
- Matthieu Beuvelet (ORCID: https://orcid.org/0000-0001-5450-3613)
Institutions
- Ithaka Harbors (US)
- BG Group (United Kingdom) (GB)
- Sanofi (France) (FR)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1007/s40121-024-01037-7
- Citations
- 12
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 4.64